Partners - Experimental Therapeutics Lab
- Institute for Research in Biomedicine (IRB)
- Oncology Institute of Southern Switzerland (IOSI)
- Ente Ospedaliero Cantonale (EOC)
- Università della Svizzera italiana (USI)
- Swiss National Science Foundation (SNF)
- Swiss Cancer League
- Fondazione San Salvatore
- Fondazione Barletta
- Fondazione Ticinese per la Ricerca sul Cancro
- EU COST Action CA17140 "Cancer Nanomedicine: from the bench to the bedside. Nano2Clinic. Working group (WG3) on Preclinical studies of nanodrugs
- International Centre for Genetic Engineering and Biotechnology (ICGEB) Cape Town, SA
- Prof. Bernhard Wünsch, PhD, Institute of Pharmaceutical and Medicinal Chemistry, Westfälische Wilhelms-Universität, Münster, Germany
- Prof. Sabrina Pricl, MolBNL@UniTS – DEA University of Trieste, Italy
- Prof. Jonathan Hall,Department of Chemistry and Applied Biosciences, ETH Zurich
- Institute for Pharmaceutical Sciences, ETH Zurich
- Prof. Rana Sanyal, Bogazici University, Department of Chemistry Bebek, Turkey